12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Inovio preclinical data

In tumor-bearing mice, animals treated with Inovio's hTERT DNA cancer vaccine delivered using the company's Cellectra intradermal electroporation device had significantly smaller tumors compared to untreated controls at all days post-challenge out to day 35...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >